This Prudential Standard, HPS 117 Capital Adequacy: Asset Concentration Risk Charge, prescribes a method and limits for calculating a capital charge that private health insurers must hold against concentrations in asset exposures. The Standard is made by APRA under subsection 92(1) of the Private Health Insurance (Prudential Supervision) Act 2015 and takes effect 1 July 2023 (Authority and Application and commencement, paras 1-4). It applies to all private health insurers and, except where otherwise noted, must be applied separately to each health benefits fund and to the general fund (para 3).

Mechanically, the Standard defines the Asset Concentration Risk Charge as the minimum capital required to cover the risk that an insurer’s exposures concentrated in a single asset, counterparty or group of related counterparties might produce adverse movements in the fund’s capital base (Objectives table; para 8). Exposures for the charge include all on- and off-balance sheet items of a fund, converted to Australian dollars as at the reporting date, and on-balance sheet items should be net of regulatory adjustments required by Prudential Standard HPS 112 (paras 9-11). The Standard also requires consistency with any look-through basis used under HPS 114 (para 12).

The Standard provides numeric and dollar limits in Attachment A. For reinsurance exposures the limits are tiered by counterparty grade: no limit for reinsurers graded 1-3, 50 percent of the capital base for grade 4, and 25 percent of the capital base for grades 5-7 (Attachment A Table 1). For non-reinsurance exposures Attachment A sets out (a) no limit for government counterparties with grade 1 or 2, (b) for related APRA-regulated parties the greater of $22.5 million and 100 percent of capital base, (c) for unrelated APRA-regulated parties a split short-term/long-term set of sub-limits with the aggregate greater of $22.5 million and 100 percent of capital base, and (d) a 25 percent of capital base limit for all other exposures (Attachment A Table 2).

The Standard prescribes how to aggregate exposures for groups of related counterparties (para 13) and a stepwise layering method for calculating reinsurance exposure charges (paras 19-21). It also sets out when collateral or guarantees permit treating an exposure as if it were to the collateral or guarantor rather than the underlying counterparty, and imposes conditions on eligible collateral, guarantees and letters of credit (paras 22-33). Special, stricter requirements apply to reinsurance recoverables due from non-APRA-authorised reinsurers, including the form and location of eligible collateral and that it not be available to other creditors (paras 28-33). APRA retains written discretion to vary limits on application and to adjust or exclude specific requirements (paras 35-36).

In short, HPS 117 converts concentration exposures into a capital amount by reference to specified grading, dollar floors and percentage limits of the capital base, prescribes treatment of mitigating instruments, places responsibilities on Boards to hold adequate capital, and gives APRA supervisory discretion for case-by-case adjustments.

The Standard rests on several discrete concepts that determine how an insurer’s exposures are measured and charged. First, exposures are comprehensive. The Asset Concentration Risk Charge covers “all on- and off-balance sheet exposures” of a fund (para 9). On-balance sheet items must be net of regulatory adjustments required by HPS 112, meaning that the same capital measurement adjustments required under HPS 112 flow through to this calculation (para 9). All exposures must be converted to Australian dollars as at the reporting date (para 10).

Second, the charge is a minimum capital requirement and a component of the prescribed capital amount. The Objectives and key requirements identify the Asset Concentration Risk Charge as “the minimum amount of capital required to be held against asset concentration risks” and a component of the prescribed capital amount (Objectives table). Responsibility for capital management is allocated to the insurer’s Board; the Board must ensure adequacy of capital commensurate with the business’s scale, nature and complexity (Objectives table).

Third, the Standard distinguishes reinsurance exposures from non-reinsurance exposures and treats them differently. Reinsurance recoverables are “assets of the fund” for this purpose (para 14), but reinsurance exposures follow the limits in Attachment A Table 1, which are tiered by counterparty grade (Attachment A Table 1). Non-reinsurance exposures follow Attachment A Table 2, which differentiates governments, related APRA-regulated parties, unrelated APRA-regulated parties (with sub-limits for short-term and long-term), and “all other exposures” (Attachment A Table 2).

Fourth, the Standard uses counterparty grading and APRA-regulated status. The counterparty grading framework is referenced from HPS 001 Definitions (paras 5 and 6(a)), and APRA-regulated counterparties or groups are identified by their authorisation under specified Acts: the Act for private health insurers, Insurance Act 1973 for general insurers and NOHCs, Banking Act 1959 for ADIs and NOHCs, and Life Insurance Act 1995 for life companies and NOHCs (para 15).

Fifth, the treatment of mitigation instruments is tightly defined. Eligible Collateral Items are cash, government securities or specified debt obligations where the collateral counterparty has a counterparty grade of 1, 2 or 3 (para 6(a); para 24). Collateral must be a registered charge, registered mortgage or other legally enforceable security interest, held for at least the period the asset is held (paras 23-24). Guarantees must be explicit, unconditional and irrevocable, and guarantees by a parent or related entity are generally excluded from eligibility (paras 26-27, 31-32). For reinsurance recoverables due from non-APRA-authorised reinsurers eligible collateral must meet additional Australian-location and insolvency-isolation criteria and be effective for the expected period of claim payment or a minimum staged period (paras 28-33).

The Standard applies to every private health insurer subject to the Private Health Insurance (Prudential Supervision) Act 2015, unless expressly noted otherwise (paras 1-3). Application is fund-specific: insurers must apply the Standard separately to each of their health benefits funds and to the general fund unless stated otherwise. That means multi-fund insurers must calculate and hold the Asset Concentration Risk Charge on a per-fund basis rather than on a consolidated insurer basis (para 3).

Directly affected actors include:

• Private health insurers and their Boards: Boards hold the ultimate responsibility for capital management and must ensure adequate capital commensurate with the fund’s scale, nature and complexity, including capital held to meet the Asset Concentration Risk Charge (Objectives table).

• Fund-level finance, risk and actuarial teams: these teams must identify, measure and report on all on- and off-balance sheet exposures per fund, perform AUD conversions as at reporting dates, apply netting or regulatory adjustments required by HPS 112, use the correct look-through approach consistent with HPS 114, and classify counterparties by grade and APRA-regulated status (paras 9-12).

• Reinsurers and non-APRA-authorised reinsurers: reinsurers are treated differently from other counterparties, and reinsurance recoverables from non-APRA-authorised reinsurers are subject to distinct collateral and guarantee rules that may materially affect reinsurance terms and availability (paras 14, 28-34; Attachment A Table 1).

• Custodians, trustees and counterparties providing collateral: eligible collateral against non-APRA recoverables must meet registration and Australia-location requirements and not be available to other creditors in insolvency (paras 24, 28-30). That may affect what collateral instruments insurers will accept and how they structure reinsurance or letters of credit arrangements.

• Parent companies and related entities: guarantees and letters of credit from related parties are excluded from eligibility under certain paragraphs (paras 27, 32), so intra-group arrangements will not always mitigate charges.

• APRA: the regulator administers, reviews and may vary or waive provisions in writing, and may require specific treatments for a fund in respect of certain reinsurance recoverables (paras 7, 34, 35-36).

Indirectly affected stakeholders include policyholders, because insurers bear the cost of holding additional capital and complying with the Standard; insurers may adjust product, investment or pricing decisions in response. Providers of capital and counterparties that are highly rated (counterparty grade 1-3) will be relatively more attractive since limits are more relaxed for them (Attachment A Table 1 and Table 2). Conversely, exposure to lower-graded counterparties and non-APRA-authorised reinsurers becomes more capital-intensive or operationally constrained.

Duties under the Standard are allocated principally to private health insurers and their Boards, with APRA exercising supervisory powers and rights to adjust application. Key duties and rights, anchored to specific provisions, follow.

Duties of insurers and their Boards:

• Maintain adequate capital for asset concentration risk, as a minimum component of prescribed capital, commensurate with scale, nature and complexity (Objectives table). The Board bears ultimate responsibility for this.
• Apply the Standard separately to each health benefits fund and the general fund (para 3).
• Include all on- and off-balance sheet exposures in the calculation, convert to AUD at reporting date and net on-balance sheet exposures of regulatory adjustments required under HPS 112 (paras 9-10).
• Ensure exposures are not double-charged: any portion of an exposure subject to the Asset Concentration Risk Charge must not be subject to the Asset Risk Charge in HPS 114; the portion not subject to the Asset Concentration Risk Charge must be subject to the Asset Risk Charge (para 11).
• Use a consistent look-through basis between HPS 114 and this Standard if that approach has been adopted under HPS 114 (para 12).
• Classify counterparties and groups in accordance with the group-of-related-counterparties definition, which includes cross guarantees, common ownership or management, control under accounting standards, financial interdependency and other connections that in the insurer’s assessment constitute a single risk (para 13).
• Apply the specified calculation methods for reinsurance and non-reinsurance exposures, including the stepwise aggregation for reinsurance exposures of groups of related counterparties (paras 17-21).
• Satisfy specific legal and location requirements where collateral is relied upon, particularly for reinsurance recoverables from non-APRA-authorised reinsurers (paras 23-33).

Rights and discretions:

• Private health insurers may elect treatment options in certain circumstances. For example, where eligible collateral or qualifying guarantees exist, an insurer may treat the underlying asset as an exposure to the collateral or guarantor rather than the underlying counterparty (paras 23-27). For reinsurance recoverables from non-APRA-authorised reinsurers, insurers may elect to apply the collateral/guarantee treatment or alternatively apply the counterparty grade of the non-APRA-authorised reinsurer (para 34).

The Prudential Standard itself sets out obligations and APRA’s supervisory powers; it does not specify criminal penalties or monetary fines in the text provided. Enforcement mechanisms are implicit in the statutory framework that authorises APRA to make the Standard under subsection 92(1) of the Private Health Insurance (Prudential Supervision) Act 2015 (Authority, para 1). Enforcement in practice will flow from APRA’s broader prudential powers under the Act and related legislation, which commonly include directions, conditions on authorisation, and other regulatory actions. The Standard also creates obligations that, if breached, would inform APRA exercise of supervisory powers such as requiring remediation, imposing conditions, or other measures APRA is authorised to use under the Act.

Specific supervisory mechanisms and discretion in the Standard:

• APRA’s written discretion: where the Standard requires APRA to exercise a power or discretion, APRA must do so in writing (para 7). This channels enforcement and supervisory decisions into documented written instruments.
• Variation and conditioning: APRA may grant applications to vary Attachment A limits and may specify conditions and periods for any such variation (para 35). That provides APRA with a regulatory tool that can be used to mitigate non-compliance risks or to permit temporary relief under conditions.
• Adjustment or exclusion: APRA may, by written notice, adjust or exclude a specific requirement in the Prudential Standard for a private health insurer (para 36). That is an explicit enforcement or supervisory lever permitting case-by-case tailoring or remedial adjustments.

Operationally, non-compliance with the Standard’s capital requirements would affect a private health insurer’s prudential standing. APRA’s typical supervisory responses under prudential regimes include requiring capital restoration plans, imposing directions, restricting distributions, or, in serious cases, varying or revoking authorisation. The Standard’s requirement that the Board ensure adequate capital (Objectives table) frames such actions as governing the prudential responsibilities of directors, and failure may inform APRA’s exercise of powers under the Act.

The Standard introduces compliance-critical features that, if not satisfied, will be reviewable by APRA: correct exposure mapping (on/off balance and look-through consistent), correct classification of counterparties and related groups, validity and enforceability of collateral and guarantees, and correct application of Attachment A limits and calculation methods (paras 9-21, 23-34). Where collateral or guarantees do not meet the Standard’s legal form, location, insolvency isolation or term requirements, APRA may treat the exposure as to the underlying counterparty and that will increase the capital charge.

HPS 117 is explicitly designed to operate alongside other APRA prudential standards and interacts with statutory authorisations under various Acts. The Standard references and incorporates other prudential obligations and statutory statuses which change where and how exposures are treated.

Interaction with other APRA prudential standards:

• HPS 112 Capital Adequacy: Measurement of Capital. The Standard requires on-balance sheet exposures to be net of regulatory adjustments “expressly related to the items that are required under Prudential Standard HPS 112” (para 9). This ties the asset concentration calculation to the same capital deduction and recognition rules used in HPS 112, ensuring consistency between capital measurement and concentration charging.
• HPS 114 Capital Adequacy: Asset Risk Charge. The Standard prohibits double-charging: any portion of an exposure subject to the Asset Concentration Risk Charge must not be subject to the Asset Risk Charge in HPS 114, and any portion not subject to the Asset Concentration Risk Charge must be subject to the Asset Risk Charge (para 11). This cross-reference creates an operational requirement to split exposures between the two regimes and ensures complementary coverage rather than overlap.
• HPS 001 Definitions. Terms defined in HPS 001, such as counterparty grades, are used in this Standard (para 5). Counterparty grades determine limits in Attachment A and the eligibility of collateral/guarantees.

Interaction with prudential authorisation and statutory regimes:

• APRA-regulated status. Attachment A classifies certain counterparties as “APRA-regulated or part of an APRA-regulated group” by reference to their authorisation under various statutes: the Private Health Insurance (Prudential Supervision) Act 2015 (private health insurers), the Insurance Act 1973 (general insurers and authorised NOHCs), the Banking Act 1959 (ADIs and authorised NOHCs) and the Life Insurance Act 1995 (life companies and authorised NOHCs) (para 15). This means that the statutory authorisation status under those Acts changes the applicable concentration limits under HPS 117.
• Insolvency and trust law. For reinsurance recoverables from non-APRA-authorised reinsurers, eligible collateral must be held in Australia as part of a trust maintained by an Australian-resident trustee, or in specified deposit forms, and must not be available to other creditors in insolvency (para 29). These requirements implicate trust law, security registration regimes, and cross-border insolvency considerations. The effectiveness of collateral in insolvency is a legal question outside the Standard that insurers must resolve in law when structuring collateral arrangements.

The instrument is identified as Health Insurance (prudential standard) determination No. 6 of 2023 and was signed on 24 May 2023 by a delegate of APRA, Helen Rowell, Deputy Chair, and it commences on 1 July 2023 (preamble and Application and commencement, paras 1-4). The Standard is made under subsection 92(1) of the Private Health Insurance (Prudential Supervision) Act 2015 (Authority, para 1). The text provided does not include any prior versions or tracked amendments to HPS 117; it is presented as the Prudential Standard determined in 2023.

Procedural features relevant to amendment and variation:

• APRA may approve applications by insurers to vary the application of Attachment A limits; in considering an application APRA will have regard to exposure type, term, ability to mitigate the charge by other means and any other matters APRA considers relevant. Approvals may be subject to conditions and time limits (para 35). That process is the built-in mechanism for insurer-specific variations short of an amendment to the Standard itself.
• APRA also has the power, by written notice, to adjust or exclude specific requirements of the Standard in relation to a private health insurer (para 36). This allows APRA to tailor supervisory requirements to particular insurers without formally amending the Standard’s text.
• Where APRA is to exercise a power or discretion under the Standard, it must exercise that power or discretion in writing (para 7). This formalises the mechanism by which adjustments or variations operate and creates a record for supervisory decisions.

The Standard does not set out a formal amendment schedule or transitional arrangements in the text provided, beyond stating the commencement date. No prior amendment history, explanatory memoranda or second-reading materials are included in the instrument text supplied. Future amendments to HPS 117 would typically follow APRA’s published processes for prudential standard changes, but those processes and timelines are not specified in this document.

Given APRA’s ability to grant insurer-specific variation and to adjust or exclude requirements in writing, insurers should consider those supervisory mechanisms when planning near-term compliance or when existing contractual arrangements (for example legacy reinsurance or collateral structures) conflict with the Standard’s treatment.

The text provided contains no litigation history. The Standard cites no cases and does not reference judicial decisions as part of its reasoning or implementation. There is no record in this instrument of prior legal challenges to HPS 117, nor are any court or tribunal outcomes mentioned.

Where the Standard’s provisions give rise to disputes in practice,such as the legal effectiveness of collateral in insolvency, the enforceability of guarantees, or the legal classification of a group of related counterparties,those issues would be resolved under applicable law (trust law, insolvency law, contract law, accounting standards) in courts or tribunals as necessary. The Standard itself does not prescribe dispute resolution paths beyond APRA’s supervisory discretion and written decisions (paras 7, 34-36).

Practitioners should therefore be aware that legal questions of enforceability, statutory interpretation of APRA notices, and conflicts between contractual terms and the Standard’s requirements may become litigated but no such litigation is referenced in the instrument. Any litigated clarification of terms such as “effective security against liabilities”, “not available for distribution to creditors” or the exact legal nature of “registered charge” is outside the text and would require review of case law as it develops.

The Standard contains several technical traps and operational pitfalls that can produce materially different capital outcomes if missed. These are practical issues that, in the absence of careful attention, can lead to misapplication or underestimation of required capital.

1. Fund-level application and aggregation. The Standard applies separately to each fund within an insurer (para 3), so treating concentrations on a consolidated insurer basis instead of fund-by-fund will understate charges. Insurers with multiple funds must perform per-fund mapping and cannot aggregate to avoid limits.

2. On- and off-balance sheet breadth and netting. Exposures include all on- and off-balance sheet items (para 9). On-balance sheet items must be net of regulatory adjustments required under HPS 112 (para 9). If teams apply inconsistent netting or omit off-balance sheet exposures (for example, undrawn facilities, letters of credit, or derivatives) the Asset Concentration Risk Charge will be miscalculated.

3. Conversion to AUD and valuation timing. All exposures must be converted to AUD as at the reporting date (para 10). Exchange rate timing mismatches or inconsistent fair value bases can lead to reporting differences and capital volatility if not managed.

4. Double-charging and allocation between HPS 114 and HPS 117. Paragraph 11 explicitly prohibits subjecting the same portion of exposure to both the Asset Concentration Risk Charge and the Asset Risk Charge in HPS 114. Insurers must define and document which portion of an exposure is subject to which charge. Failure to segregate correctly may either double-charge or leave portions uncharged.

5. Look-through consistency. If a look-through approach is used under HPS 114, the same look-through must be used here (para 12). Different teams or systems using inconsistent look-through assumptions will produce reconciliation issues and possible regulatory attention.

6. Group of related counterparties is fact-specific. The definition in para 13 includes elements like cross guarantees, common ownership or management, control under accounting standards, financial interdependency, and other connections that in the insurer’s assessment constitute a single risk. That assessment requires legal and commercial judgement and must be documented. An overly narrow or broad interpretation will change aggregation and limits.

7. Collateral enforceability and registration. For collateral to be recognised against non-reinsurance assets, it must be a registered charge, registered mortgage or other legally enforceable security interest, and the Eligible Collateral Item must have a counterparty grade 1-3 and be held for a period not less than the asset term (paras 23-24). Informal or unregistered security arrangements, overseas collateral not registered in Australia, or collateral with shorter availability than the asset will not qualify.

This section sets out a procedural compliance checklist and practical steps tied to the Standard’s provisions. The objective is to produce a repeatable, auditable process that satisfies HPS 117 requirements.

1. Governance and oversight

• Confirm the Board’s oversight role and document capital adequacy responsibilities in board papers, consistent with the Objectives table. Ensure the Board signs off on methodology and any APRA applications for variation (Objectives table; paras 35-36).
• Nominate accountable officials for fund-level calculations and for interaction with APRA, documenting responsibilities.

2. Fund-level mapping

• Identify each fund (health benefits funds and general fund) and confirm that calculations will be performed separately for each fund (para 3).
• Compile a full inventory of exposures for each fund: all on-balance sheet items net of HPS 112 regulatory adjustments, and all off-balance sheet exposures (para 9). Ensure systems capture contingent items, letters of credit, undrawn facilities, derivatives and reinsurance recoverables.

3. Classification and grading

• Determine the counterparty grade for each counterparty using HPS 001 grading rules and document the basis (para 6(a); para 5). Where counterparties are APRA-regulated or part of an APRA-regulated group, classify them according to para 15 criteria.
• Assess group-of-related-counterparties status for counterparties linked by cross guarantees, common ownership/management, control under accounting standards, financial interdependency or other connections and document the assessment (para 13). Legal counsel should verify control and guarantee structures.

4. Currency conversion and valuation

• Convert all exposures to AUD as at the reporting date and adopt a consistent valuation basis (para 10). Document FX rates and valuation methodologies and reconcile monthly and year-end positions.

5. Look-through consistency

• If a look-through basis is used for assets under HPS 114, adopt the exact same look-through methodology and document it for auditability (para 12).

6. Collateral and guarantee verification

• For any collateral relied upon for mitigation, verify it meets the Standard’s legal form requirements: registered charge, registered mortgage or legally enforceable security interest (para 24). Ensure Eligible Collateral Items are restricted to those permitted and that the collateral counterparty has grade 1-3 where required (para 6(a); para 24).